Cagrilintide
The sentences below are limited to one FDA page opened for this draft.
What the opened sources say
Section titled “What the opened sources say”- FDA says cagrilintide cannot be used in compounding under federal law, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition.
- The same FDA page’s sentence about false research-use labels names semaglutide, tirzepatide, retatrutide, survodutide, and mazdutide. It does not name cagrilintide in that sentence. This page does not add it.
Not stated here
Section titled “Not stated here”Combination products and trial names are not summarized. A standard Chinese generic name was not checked, so the Chinese title keeps the English name.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (primary, accessed 2026-11-20)
Referenced by
A link from another wiki page is not evidence. Facts should point at the sources above.